Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (13373) 13373
Publication (1703) 1703
Newspaper Article (518) 518
Book Review (188) 188
Book Chapter (149) 149
Book / eBook (119) 119
Dissertation (38) 38
Conference Proceeding (24) 24
Trade Publication Article (15) 15
Magazine Article (9) 9
Data Set (8) 8
Government Document (6) 6
Newsletter (4) 4
Paper (4) 4
Report (3) 3
Web Resource (3) 3
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (8998) 8998
index medicus (7091) 7091
pharmacology & pharmacy (5575) 5575
male (5418) 5418
female (5392) 5392
population (4886) 4886
population pharmacokinetics (4129) 4129
pharmacokinetics (3912) 3912
adult (3856) 3856
middle aged (3335) 3335
aged (2523) 2523
analysis (1995) 1995
models, biological (1932) 1932
pharmacology (1882) 1882
research (1832) 1832
animals (1617) 1617
adolescent (1597) 1597
children (1288) 1288
studies (1286) 1286
young adult (1262) 1262
health aspects (1244) 1244
dose-response relationship, drug (1217) 1217
child (1206) 1206
metabolism (1206) 1206
toxicology (1197) 1197
medicine (1159) 1159
pharmacodynamics (1131) 1131
pharmacology/toxicology (1096) 1096
drug therapy (1087) 1087
drug dosages (1081) 1081
research article (1068) 1068
genotype (1047) 1047
patients (1047) 1047
aged, 80 and over (1012) 1012
care and treatment (960) 960
infectious diseases (934) 934
risk factors (897) 897
pharmacogenetics (889) 889
drugs (874) 874
microbiology (847) 847
oncology (833) 833
child, preschool (817) 817
cancer (811) 811
therapy (808) 808
pediatrics (793) 793
environmental sciences (788) 788
treatment outcome (778) 778
multidisciplinary sciences (774) 774
computer simulation (766) 766
science (743) 743
age (737) 737
dosage and administration (726) 726
infant (717) 717
pharmacy (713) 713
area under curve (704) 704
clinical trials (702) 702
models (675) 675
nonmem (659) 659
safety (653) 653
biomedicine (643) 643
medicine & public health (641) 641
genetic aspects (636) 636
medical research (627) 627
metabolites (624) 624
exposure (612) 612
administration, oral (609) 609
article (607) 607
polymorphism (597) 597
public, environmental & occupational health (591) 591
drug interactions (589) 589
retrospective studies (588) 588
risk (568) 568
toxicity (563) 563
usage (560) 560
mortality (555) 555
internal medicine (553) 553
chemotherapy (549) 549
efficacy (548) 548
populations (547) 547
epidemiology (545) 545
physiological aspects (538) 538
algorithms (532) 532
age factors (523) 523
anti-bacterial agents - pharmacokinetics (514) 514
infant, newborn (512) 512
population studies (507) 507
prospective studies (505) 505
plasma (504) 504
time factors (502) 502
adults (499) 499
infections (497) 497
body weight (493) 493
polymorphism, genetic (489) 489
model (485) 485
infants (468) 468
models, statistical (466) 466
metabolic clearance rate (463) 463
bioavailability (461) 461
enzymes (460) 460
medicine and health sciences (460) 460
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (72) 72
UofT at Mississauga - Stacks (14) 14
Collection Dvlpm't (Acquisitions) - Vendor file (13) 13
UofT at Scarborough - Stacks (13) 13
Collection Dvlpm't (Acquisitions) - Closed Orders (12) 12
Robarts - Stacks (6) 6
Law (Bora Laskin) - Stacks (5) 5
Online Resources - Online (5) 5
UTL at Downsview - May be requested (4) 4
New College (Ivey) - Stacks (3) 3
OISE - Stacks (3) 3
St. Michael's College (John M. Kelly) - 2nd Floor (3) 3
Engineering & Comp. Sci. - Reference (2) 2
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (2) 2
UofT at Mississauga - Reference (2) 2
Credit Valley Hospital - Stacks (1) 1
Earth Sciences (Noranda) - Reference (1) 1
Engineering & Comp. Sci. - Stacks (1) 1
Gerstein Science - Reference (1) 1
Humber River Regional Hospital - Finch Stacks (1) 1
Law (Bora Laskin) - Closed Orders (1) 1
Law (Bora Laskin) - Reserve desk (1) 1
Markham Stouffville Hospital - Stacks (1) 1
Mathematical Sciences - Stacks (1) 1
OISE - Bindery (1) 1
Providence Healthcare - Reference (1) 1
Providence Healthcare - Stacks (1) 1
Robarts - Not Returned (1) 1
Royal Ontario Museum - Stacks (1) 1
Scarborough Hospital - General (1) 1
St. Michael's College (John M. Kelly) - Reference (1) 1
Stacks (1) 1
Sunnybrook Health Sciences Centre - Holland Stacks (1) 1
West Park Healthcare Centre - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (13968) 13968
French (80) 80
Spanish (47) 47
Japanese (46) 46
German (38) 38
Russian (16) 16
Chinese (10) 10
Korean (5) 5
Portuguese (5) 5
Italian (4) 4
Dutch (3) 3
Croatian (2) 2
Slovenian (2) 2
Swedish (2) 2
Danish (1) 1
Greek (1) 1
Polish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Developmental pharmacokinetics of ciclosporin a population pharmacokinetic study in paediatric renal transplant candidates
by Fanta, S and Jonsson, S and Backman, J. T and Karlsson, M. O and Hoppu, K and Medicinska och farmaceutiska vetenskapsområdet and Institutionen för farmaceutisk biovetenskap and Uppsala universitet and Avdelningen för farmakokinetik och läkemedelsterapi and Farmaceutiska fakulteten
British Journal of Clinical Pharmacology, ISSN 0306-5251, 12/2007, Volume 64, Issue 6, pp. 772 - 784
What is already known about this subject • Ciclosporin is an immunosuppressant drug with a narrow therapeutic index and large variability in pharmacokinetics.•... 
developmental | ciclosporin (cyclosporine A) | CYP3A4 | renal transplantation | paediatric | population pharmacokinetics | Developmental | Renal transplantation | Paediatric | Population pharmacokinetics | Ciclosporin (cyclosporine A) | RECIPIENTS | CHILDREN | VARIABILITY | THERAPY | RISK-FACTOR | METABOLISM | DRUG DISPOSITION | PHARMACOLOGY & PHARMACY | KIDNEY | HUMAN-LIVER | Age Factors | Models, Biological | Humans | Adolescent | Child, Preschool | Cyclosporine - pharmacokinetics | Infant | Kidney Transplantation | Metabolic Clearance Rate - drug effects | Child | Metabolic Clearance Rate - physiology | Databases, Factual | Medicine, Experimental | Medical research | Transplantation | Kidneys | Cyclosporine | Analysis | Pharmacokinetics in Renal Transplantation | Pharmaceutical Sciences | Basic Medicine | PHARMACY | Medical and Health Sciences | Medicin och hälsovetenskap | Farmaceutiska vetenskaper | Medicinska och farmaceutiska grundvetenskaper | FARMACI
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Pharmacokinetics
by Bonate, Peter L
Wiley Interdisciplinary Reviews: Computational Statistics, ISSN 1939-5108, 07/2011, Volume 3, Issue 4, pp. 332 - 342
Pharmacokinetics is the study of the absorption, distribution, metabolism, and excretion of drugs. Simply put, pharmacokinetics is what the body does to the... 
drug development | package insert | exposure‐response | Phase 1 | pharmacometrics | Drugs | Excretion | Pharmacodynamics | Statistical analysis | Data processing | Pharmacology | Biology | Metabolism | Drug development | Statistics | Population (statistical) | Computation | Computer applications | Chemical kinetics | Drug metabolism | Molecular biology | Pharmacokinetics
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text A model‐based approach to characterize the population pharmacokinetics and the relationship between the pharmacokinetic and safety profiles of RBP‐7000, a new, long‐acting, sustained‐released formulation of risperidone
by Gomeni, R and Heidbreder, C and Fudala, P.J and Nasser, A.F
The Journal of Clinical Pharmacology, ISSN 0091-2700, 10/2013, Volume 53, Issue 10, pp. 1010 - 1019
RBP‐7000 is a sustained‐release (once‐monthly injection for subcutaneous administration) formulation of risperidone using the ATRIGEL® Delivery System,... 
long‐acting risperidone | prolactin levels | D2 receptor occupancy | Prolactin levels | Long-acting risperidone | ANTIPSYCHOTICS | IMPLEMENTATION | SCHIZOPHRENIA | PHARMACOLOGY & PHARMACY | long-acting risperidone | OCCUPANCY | NONMEM | Schizophrenia - metabolism | Pyrimidines - blood | Antipsychotic Agents - adverse effects | Humans | Middle Aged | Risperidone - pharmacokinetics | Delayed-Action Preparations - chemistry | Male | Receptors, Dopamine D2 - metabolism | Delayed-Action Preparations - administration & dosage | Young Adult | Schizophrenia - genetics | Injections, Subcutaneous | Delayed-Action Preparations - pharmacokinetics | Risperidone - adverse effects | Isoxazoles - blood | Adult | Female | Polyglactin 910 - chemistry | Cytochrome P-450 CYP2D6 - genetics | Risperidone - administration & dosage | Paliperidone Palmitate | Risperidone - chemistry | Antipsychotic Agents - pharmacokinetics | Antipsychotic Agents - administration & dosage | Prolactin - blood | Antipsychotic Agents - chemistry | Delayed-Action Preparations - adverse effects | Models, Biological | Adolescent | Schizophrenia - drug therapy | Dosage and administration | Safety and security measures | Research | Risperidone | Pharmacokinetics | Pituitary gland | Population | Rodents
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Pharmacokinetic Variability of Newer Antiepileptic Drugs: When is Monitoring Needed?
by Johannessen, Svein I and Tomson, Torbjorn
Clinical Pharmacokinetics, ISSN 0312-5963, 2006, Volume 45, Issue 11, pp. 1061 - 1075
A new generation of antiepileptic drugs (AEDs) has reached the market in recent years with ten new compounds: felbamate, gabapentin, lamotrigine,... 
Topiramate | Felbamate | Gabapentin | Epilepsy | Drug monitoring | Pregabalin | Zonisamide | Oxcarbazepine | Tiagabine | Vigabatrin | Antiepileptic drugs | Lamotrigine | Levetiracetam | Pharmacotherapy | Internal Medicine | Medicine & Public Health | Pharmacology/Toxicology | HEALTHY-SUBJECTS | POPULATION PHARMACOKINETICS | LAMOTRIGINE SERUM CONCENTRATIONS | PEDIATRIC-PATIENTS | PHARMACOLOGY & PHARMACY | TO-DOSE RATIO | EPILEPTIC PATIENTS | STEADY-STATE | PARTIAL SEIZURES | RETROSPECTIVE ANALYSIS | CLINICAL-RESPONSE | Isoxazoles - pharmacokinetics | Anticonvulsants - blood | Anticonvulsants - pharmacokinetics | Fructose - pharmacokinetics | Carbamazepine - analogs & derivatives | Humans | Propylene Glycols - pharmacokinetics | Phenylcarbamates - pharmacokinetics | Piracetam - pharmacokinetics | Fructose - analogs & derivatives | Drug Interactions | Nipecotic Acids - pharmacokinetics | Vigabatrin - pharmacokinetics | Piracetam - analogs & derivatives | Amines - pharmacokinetics | Epilepsy - drug therapy | Cyclohexanecarboxylic Acids - pharmacokinetics | Carbamazepine - pharmacokinetics | Drug Monitoring | gamma-Aminobutyric Acid - analogs & derivatives | Epilepsy - blood | Triazines - pharmacokinetics | gamma-Aminobutyric Acid - pharmacokinetics
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Monoclonal Antibody Pharmacokinetics and Pharmacodynamics
by Wang, W and Wang, EQ and Balthasar, JP
Clinical Pharmacology & Therapeutics, ISSN 0009-9236, 11/2008, Volume 84, Issue 5, pp. 548 - 558
More than 20 monoclonal antibodies have been approved as therapeutic drugs by the US Food and Drug Administration, and it is quite likely that the number of... 
NUDE-MICE | CLEARANCE | NEONATAL FC-RECEPTOR | MICE BEARING | POPULATION PHARMACOKINETICS | VOLUME | IGG | PHARMACOLOGY & PHARMACY | MECHANISMS | MODEL | PSORIASIS | Immunoglobulins - physiology | Antibodies, Monoclonal - pharmacology | Humans | Antibodies, Monoclonal - pharmacokinetics | Half-Life | Biological Availability | Metabolic Clearance Rate | Immunoglobulins - metabolism | Tissue Distribution | Immunoglobulins - classification | Immunologic Factors - pharmacokinetics | Absorption | Animals | Models, Biological | Antibodies, Monoclonal - metabolism | Immunologic Factors - metabolism | Immunologic Factors - pharmacology | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Paediatric pharmacokinetics: key considerations
by Batchelor, Hannah Katharine and Marriott, John Francis
British Journal of Clinical Pharmacology, ISSN 0306-5251, 03/2015, Volume 79, Issue 3, pp. 395 - 404
A number of anatomical and physiological factors determine the pharmacokinetic profile of a drug. Differences in physiology in paediatric populations compared... 
clinical trial | pharmacokinetics | paediatric drug development | biopharmaceutics | absorption | paediatric | SCAVENGED SAMPLES | PRETERM INFANTS | NEWBORN-INFANT | DRUG-METABOLIZING-ENZYMES | CLINICAL PHARMACOKINETICS | CHILDREN | POPULATION PHARMACOKINETICS | ONTOGENY | AGE-GROUPS | PHARMACOLOGY & PHARMACY | INTESTINAL PERMEABILITY | Tissue Distribution | Inactivation, Metabolic | Pediatrics | Pharmaceutical Preparations - blood | Pharmaceutical Preparations - metabolism | Models, Biological | Humans | Pharmaceutical Preparations - urine | Clinical Trials as Topic | Pharmacokinetics | Child | Intestinal Absorption | Pediatric pharmacology | Analysis | Themed Section - Paediatric Prescribing
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Pharmacokinetics and Pharmacodynamics of GS-9350: A Novel Pharmacokinetic Enhancer Without Anti-HIV Activity
by Mathias, A A and German, P and Murray, B P and Wei, L and Jain, A and West, S and Warren, D and Hui, J and Kearney, B P
Clinical Pharmacology & Therapeutics, ISSN 0009-9236, 03/2010, Volume 87, Issue 3, pp. 322 - 329
GS‐9350 is a new chemical entity under development as a potent, mechanism‐based inhibitor of human cytochrome P450 3A (CYP3A) isoforms. Its intended use is to... 
HEPATIC CYP3A | POPULATION PHARMACOKINETICS | CYP3A ACTIVITY | CYTOCHROME-P450 3A ACTIVITY | PHARMACOLOGY & PHARMACY | INFECTED PATIENTS | HIV-1-INFECTED PATIENTS | MIDAZOLAM | BOOSTED PROTEASE INHIBITORS | P-GLYCOPROTEIN | RITONAVIR | Anti-HIV Agents - pharmacology | Cytochrome P-450 Enzyme Inhibitors | Cytochrome P-450 CYP3A | Humans | Middle Aged | Male | Thiazoles - administration & dosage | Carbamates - administration & dosage | Midazolam - antagonists & inhibitors | Carbamates - pharmacokinetics | Thiazoles - pharmacokinetics | Anti-HIV Agents - administration & dosage | Dose-Response Relationship, Drug | Enzyme Inhibitors - administration & dosage | Young Adult | Enzyme Inhibitors - pharmacokinetics | Adult | Female | Pharmaceutical Preparations - administration & dosage | Carbamates - pharmacology | Cytochrome P-450 Enzyme System - blood | Anti-Retroviral Agents - pharmacokinetics | Anti-Retroviral Agents - pharmacology | Enzyme Inhibitors - pharmacology | Midazolam - pharmacokinetics | Drug Synergism | Cytochrome P-450 CYP3A Inhibitors | Anti-HIV Agents - pharmacokinetics | Anti-Retroviral Agents - administration & dosage | Adolescent | Thiazoles - pharmacology | Midazolam - pharmacology | Cobicistat | Isoenzymes - antagonists & inhibitors | Cohort Studies | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Clinical Pharmacokinetics and Pharmacodynamics of Dexmedetomidine
by Weerink, Maud A. S and Struys, Michel M. R. F and Hannivoort, Laura N and Barends, Clemens R. M and Absalom, Anthony R and Colin, Pieter
Clinical Pharmacokinetics, ISSN 0312-5963, 8/2017, Volume 56, Issue 8, pp. 893 - 913
Dexmedetomidine is an α2-adrenoceptor agonist with sedative, anxiolytic, sympatholytic, and analgesic-sparing effects, and minimal depression of respiratory... 
Pharmacotherapy | Internal Medicine | Medicine & Public Health | Pharmacology/Toxicology | ISCHEMIA-REPERFUSION INJURY | MINIMUM ALVEOLAR CONCENTRATION | INCREASING PLASMA-CONCENTRATIONS | POPULATION PHARMACOKINETICS | INTRAVENOUS DEXMEDETOMIDINE | INTRANASAL DEXMEDETOMIDINE | DOUBLE-BLIND | BRACHIAL-PLEXUS BLOCK | PHARMACOLOGY & PHARMACY | INTRAMUSCULAR DEXMEDETOMIDINE | INTENSIVE-CARE | Cardiac Output - physiology | Pediatrics | Intensive Care Units - standards | Analgesics, Non-Narcotic - pharmacokinetics | Hypnotics and Sedatives - adverse effects | Adrenergic alpha-2 Receptor Agonists - pharmacokinetics | Humans | Hypnotics and Sedatives - administration & dosage | Male | Administration, Buccal | Adrenergic alpha-2 Receptor Agonists - administration & dosage | Adrenergic alpha-2 Receptor Agonists - adverse effects | Analgesics, Non-Narcotic - adverse effects | Hypertension - chemically induced | Adult | Anesthesia | Female | Receptors, GABA - drug effects | Body Mass Index | Dexmedetomidine - administration & dosage | Hypnotics and Sedatives - pharmacokinetics | Dexmedetomidine - pharmacokinetics | Analgesics, Non-Narcotic - administration & dosage | Hypotension - chemically induced | Administration, Intranasal | Dexmedetomidine - adverse effects | Bradycardia - chemically induced | Serum Albumin, Human - physiology | Liver - physiology | Hemodynamics - drug effects | Infusions, Intravenous | Care and treatment | Analysis | Depression, Mental | Dexmedetomidine | Pharmacology | Dosage and administration | Pharmacokinetics | Systematic review | Kinases | Rodents | Review
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies
by Keizer, Ron J and Huitema, Alwin D. R and Schellens, Jan H. M and Beijnen, Jos H
Clinical Pharmacokinetics, ISSN 0312-5963, 8/2010, Volume 49, Issue 8, pp. 493 - 507
Monoclonal antibodies (mAbs) have been used in the treatment of various diseases for over 20 years and combine high specificity with generally low toxicity.... 
Pharmacotherapy | Internal Medicine | Medicine & Public Health | Pharmacology/Toxicology | pharmacokinetics | monoclonal-antibodies | drug interactions | pharmacokinetic-pharmacodynamic-relationships | EVERY 3 WEEKS | ANTI-CD11A ANTIBODY | SOLID TUMORS | POPULATION PHARMACOKINETICS | METASTATIC BREAST-CANCER | I-RELATED RECEPTOR | CHRONIC LYMPHOCYTIC-LEUKEMIA | PHASE-II | PHARMACOLOGY & PHARMACY | ANTITUMOR NECROSIS FACTOR | RHEUMATOID-ARTHRITIS PATIENTS | Drug Administration Routes | Humans | Immunologic Factors - administration & dosage | Antibodies, Monoclonal - pharmacokinetics | Antibodies, Monoclonal - therapeutic use | Mice, Knockout | Tissue Distribution | Immunologic Factors - pharmacokinetics | Absorption | Animals | Drug Interactions | Antibodies, Monoclonal - administration & dosage | Mice | Immunologic Factors - therapeutic use | Monoclonal antibodies | Complications and side effects | Dosage and administration | Pharmacokinetics | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Population Pharmacokinetics of Therapeutic Monoclonal Antibodies
by Dirks, Nathanael L and Meibohm, Bernd
Clinical Pharmacokinetics, ISSN 0312-5963, 10/2010, Volume 49, Issue 10, pp. 633 - 659
A growing number of population pharmacokinetic analyses of therapeutic monoclonal antibodies (mAbs) have been published in the scientific literature. The aims... 
Pharmacotherapy | Internal Medicine | Medicine & Public Health | Pharmacology/Toxicology | Drug-interactions | Pharmacodynamics | Monoclonal-antibodies | Population-pharmacokinetics | Pharmacokinetic-modelling | Pharmacokinetics | RHEUMATOID-ARTHRITIS | GROWTH-FACTOR RECEPTOR | MEDIATED DRUG DISPOSITION | ADVANCED SOLID TUMORS | MODEL PARAMETERS | METASTATIC BREAST-CANCER | I-RELATED RECEPTOR | IGG FC-RECEPTOR | PHARMACOLOGY & PHARMACY | LYMPHATIC ABSORPTION | IMMUNOGLOBULIN-G | Humans | Antibodies, Monoclonal - pharmacokinetics | Antibodies, Monoclonal - therapeutic use | Female | Male | Metabolic Clearance Rate | Clinical Trials as Topic | Structure-Activity Relationship | Monoclonal antibodies | Complications and side effects | Dosage and administration | Research
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights